Nosebleed News and Research

RSS

Blood protein could be a potential biomarker for delayed concussion recovery in children

Researchers have discovered a blood protein that could help detect which children will experience ongoing concussion symptoms more than two weeks after an injury.

9 Apr 2024

Study finds common adverse events between Flu and COVID-19 vaccines

A study compared the top 10 common adverse events of COVID-19 vaccines and flu vaccine’s adverse effects.

28 Sep 2021

New evidence-based clinical practice guideline for nosebleed published

The American Academy of Otolaryngology-Head and Neck Surgery Foundation published the Clinical Practice Guideline: Nosebleed (Epistaxis) today in Otolaryngology-Head and Neck Surgery.

7 Jan 2020

Clinical trial: Oral drug improves exercise capacity in teens with congenital heart defects

The largest-ever clinical trial of a medication for pediatric cardiology patients found that an oral drug significantly improved exercise capacity in adolescent patients with severe, congenital single-ventricle heart defects.

17 Nov 2019

Study shows ticagrelor is equally safe and effective as clopidogrel after heart attack

Patients given clot busters to treat a heart attack fared equally well if they were given the standard blood thinning medication clopidogrel versus the newer, more potent drug ticagrelor, according to research presented at the American College of Cardiology's 68thAnnual Scientific Session.

19 Mar 2019

Studies examine effectiveness of nasal sprays in reducing frequency, duration of HHT-related epistaxis

Two studies appearing in the September 6 issue of JAMA examine the effectiveness of nasal sprays to reduce the frequency and duration of nosebleeds caused by hereditary hemorrhagic telangiectasia (HHT), an inherited condition characterized by abnormal blood vessels which are delicate and prone to bleeding.

6 Sep 2016

Study: Cancer drug may help reduce bleeding in HHT patients

A cancer drug that helps keep tumors from growing blood vessels may help patients with a rare genetic condition in which malformed vessels increase their risk for bleeding and anemia.

17 Mar 2015

Identifying infant and toddler injuries that require emergency medical care

Bianca Edison, MD, MS is an attending physician in the Children's Orthopaedic Center at Children's Hospital Los Angeles, and is assistant clinical professor of Orthopaedics at the Keck School of Medicine of the University of Southern California. Edison is a licensed, Board-Certified pediatrician and Fellow of the American Academy of Pediatrics who completed a fellowship in Primary Care SportsMedicine. Her interests and experience include orthopaedic conditions affecting young children, teens, and athletes. Here she reviews common infant and toddler injuries, and how parents can determine if emergency medical care is needed.

2 Dec 2014

Researchers develop therapeutic algorithm to study outcomes in epistaxis management

Approximately 60 percent of people experience epistaxis, commonly known as nosebleed, at least once in their lifetime. Of those who experience nosebleed, six percent require medical treatment. A study in the September 2013 issue of Otolaryngology-Head and Neck Surgery, explores which nosebleed treatment options demonstrate the best outcomes.

27 Aug 2013

Analysts predict continued Medicare cost growth slowdown

As Medicare and Social Security's trustees prepare to release their annual report Friday, USA Today reports that the rate of increase in overall Medicare spending could continue to slow because of the 2010 health law. The Associated Press reports that a slowed upward curve only delays a day of reckoning for the popular programs, however.

1 Jun 2013

First Edition: May 31, 2013

Today's early morning highlights from the major news organizations, including reports from the administration about the number of insurers that will be offering policies on the new online marketplaces.

31 May 2013

Sunovion launches ZETONNA Nasal Aerosol for allergic rhinitis

Sunovion Pharmaceuticals Inc. today announced the nationwide availability of ZETONNA (ciclesonide) Nasal Aerosol, 74 mcg once-daily, for the treatment of allergic rhinitis (AR), also known as hay fever or nasal allergies. ZETONNA is a corticosteroid indicated for the treatment of symptoms associated with seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) in adults and adolescents 12 years of age and older.

30 Jul 2012

Bacon for nosebleeds: Case report

Ian Humphreys, Sonal Saraiya, Walter Belenky and James Dworkin, at Detroit Medical Centre in Michigan proceeded to treat a four year old girl who had a rare hereditary disorder that brings prolonged bleeding, publishing their findings in the Annals of Otology, Rhinology and Laryngology.

26 Jan 2012

Creighton researcher to study role of adult stem cells in repairing damaged coronary arteries

A Creighton University School of Medicine researcher has received a $3.3 million, five-year grant from the National Institutes of Health to study what role adult stem cells might play in repairing damaged coronary arteries, a complication that often occurs in patients after they undergo angioplasty and stenting.

24 Jan 2012

Continuous positive airway pressure machine more effective for sleep apnea patients

Among the treatments for obstructive sleep apnea, the effectiveness of a nighttime-breathing machine called a "CPAP" was backed by the strongest evidence, and a mouthpiece worn at night was also shown to be effective, according to a new report funded by HHS' Agency for Healthcare Research and Quality.

9 Aug 2011

Extreme heat and rain lead to higher mold count in the Midwest

A record 7 inches of rain combined with the spate of 100-plus-degree days has spawned the highest mold count recorded for the year, just short of an air pollution warning.

27 Jul 2011

$Updated Phase 1 study results of FOLOTYN in patients with refractory CTCL presented at ASH 2010$

Updated Phase 1 study results of FOLOTYN in patients with refractory CTCL presented at ASH 2010

Allos Therapeutics, Inc. today reported updated results from the Company's Phase 1 dose-finding study of FOLOTYN® (pralatrexate injection) which supports the selection of 15 mg/m2 weekly for three weeks out of a four-week cycle as the optimal starting dose and schedule for further evaluation in patients with relapsed or refractory cutaneous T-cell lymphoma. Data were presented at the 52nd American Society of Hematology Annual Meeting in Orlando, Florida.

6 Dec 2010

Acceleron announces ACE-031 Phase 1b study results

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced preliminary results from a Phase 1b study to assess the safety, tolerability and pharmacodynamic (PD) activity of ACE-031 following multiple ascending doses in healthy postmenopausal volunteers.

14 Oct 2010

Rebirth of the cursed drug Thalidomide

Thalidomide was once a dreaded name in the Pharmaceutical industry. It was initially marketed in some European countries nearly 5 decades back as a sedative and after millions of pregnant women took it for morning sickness it had devastating results on the babies. The babies were born with flippers instead of limbs a condition known as phocomelia. Since then it has been under strict control.

5 Apr 2010

AVASTIN receives Health Canada approval for patients with GBM

Roche Canada announced today that Health Canada has approved AVASTIN(R) (bevacizumab), as a single agent, for the treatment of patients with glioblastoma multiforme, the most aggressive primary malignant brain tumour, after relapse or disease progression, following prior therapy.

26 Mar 2010